VAXART

VXRT NASDAQ
0.6567
+0.0008
+0.12%
已收盘, 16:00 08/20 EDT
开盘
0.6568
昨收
0.6559
最高
0.6710
最低
0.6403
成交量
6.01万
成交均量(3M)
14.10万
52周最高
7.60
52周最低
0.5500
换手率
0.38%
市值
1,048.01万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供VAXART VXRT股票价格,VAXART股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.
展开 >

最近浏览

名称
价格
涨跌幅